CKLF1-C27

CKLF1-C27, a C-terminal peptide of CKLF1, binds to CCR4 receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research[1].

Product Specifications

CAS Number

[891861-48-6]

UNSPSC

12352209

Target

CCR; ERK

Type

Peptides

Related Pathways

GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/cklf1-c27.html

Purity

98.46

Solubility

H2O : ≥ 50 mg/mL

Smiles

O=C([C@H]1N(CCC1)C(CNC([C@H](CO)NC([C@H]2N(CCC2)C([C@H](CC(N)=O)NC([C@@H](NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H]([C@@H](C)CC)NC([C@H](CC(C)C)NC([C@@H](N)C)=O)=O)=O)CC3=CC=C(C=C3)O)=O)=O)=O)=O)=O)CC4=CC=CC=C4)=O)=O)=O)=O)=O)N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N6[C@@H](CCC6)C(N[C@@H](C(C)C)C(N[C@H](C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](C(C)C)C(N[C@H](C(O)=O)CC(C)C)=O)=O)=O)=O)=O)=O)CC7=CN=CN7)=O)=O)=O)=O)=O)=O

Molecular Formula

C151H243N39O37

Molecular Weight

3196.78

References & Citations

[1]Yaqi Tan, et al. Chemokine-like factor 1-derived C-terminal peptides induce the proliferation of dermal microvascular endothelial cells in psoriasis. PLoS One. 2015 Apr 27;10 (4) :e0125073.